nodes	percent_of_prediction	percent_of_DWPC	metapath
Ipratropium bromide—CYP2D6—Lomustine—hematologic cancer	0.0401	0.0738	CbGbCtD
Ipratropium bromide—CYP2D6—Idarubicin—hematologic cancer	0.0357	0.0658	CbGbCtD
Ipratropium bromide—CYP2D6—Hydroxyurea—hematologic cancer	0.0304	0.0559	CbGbCtD
Ipratropium bromide—CYP3A4—Bexarotene—hematologic cancer	0.0274	0.0505	CbGbCtD
Ipratropium bromide—CYP2D6—Bortezomib—hematologic cancer	0.0264	0.0487	CbGbCtD
Ipratropium bromide—CYP3A4—Busulfan—hematologic cancer	0.0255	0.0469	CbGbCtD
Ipratropium bromide—CYP3A4—Lomustine—hematologic cancer	0.0255	0.0469	CbGbCtD
Ipratropium bromide—CYP3A4—Thiotepa—hematologic cancer	0.0227	0.0418	CbGbCtD
Ipratropium bromide—CYP2D6—Imatinib—hematologic cancer	0.0194	0.0356	CbGbCtD
Ipratropium bromide—CYP3A4—Methoxsalen—hematologic cancer	0.0177	0.0325	CbGbCtD
Ipratropium bromide—CYP2D6—Nilotinib—hematologic cancer	0.0176	0.0324	CbGbCtD
Ipratropium bromide—CYP2D6—Vinorelbine—hematologic cancer	0.0174	0.0321	CbGbCtD
Ipratropium bromide—CYP3A4—Bortezomib—hematologic cancer	0.0168	0.0309	CbGbCtD
Ipratropium bromide—CYP3A4—Daunorubicin—hematologic cancer	0.0161	0.0296	CbGbCtD
Ipratropium bromide—CYP3A4—Cytarabine—hematologic cancer	0.0142	0.0261	CbGbCtD
Ipratropium bromide—CYP3A4—Teniposide—hematologic cancer	0.014	0.0257	CbGbCtD
Ipratropium bromide—CYP3A4—Ifosfamide—hematologic cancer	0.0129	0.0237	CbGbCtD
Ipratropium bromide—CYP3A4—Imatinib—hematologic cancer	0.0123	0.0227	CbGbCtD
Ipratropium bromide—CYP3A4—Ruxolitinib—hematologic cancer	0.0116	0.0213	CbGbCtD
Ipratropium bromide—CYP3A4—Nilotinib—hematologic cancer	0.0112	0.0206	CbGbCtD
Ipratropium bromide—CYP3A4—Vinorelbine—hematologic cancer	0.0111	0.0204	CbGbCtD
Ipratropium bromide—CYP2D6—Vinblastine—hematologic cancer	0.0108	0.0198	CbGbCtD
Ipratropium bromide—CYP3A4—Triamcinolone—hematologic cancer	0.0101	0.0187	CbGbCtD
Ipratropium bromide—CYP3A4—Dasatinib—hematologic cancer	0.00989	0.0182	CbGbCtD
Ipratropium bromide—CYP3A4—Mitoxantrone—hematologic cancer	0.00977	0.018	CbGbCtD
Ipratropium bromide—CYP3A4—Betamethasone—hematologic cancer	0.00871	0.016	CbGbCtD
Ipratropium bromide—CYP3A4—Prednisolone—hematologic cancer	0.00859	0.0158	CbGbCtD
Ipratropium bromide—CYP3A4—Prednisone—hematologic cancer	0.00811	0.0149	CbGbCtD
Ipratropium bromide—CYP2D6—Dexamethasone—hematologic cancer	0.00796	0.0147	CbGbCtD
Ipratropium bromide—CYP3A4—Irinotecan—hematologic cancer	0.00769	0.0142	CbGbCtD
Ipratropium bromide—CYP3A4—Vinblastine—hematologic cancer	0.00684	0.0126	CbGbCtD
Ipratropium bromide—CYP3A4—Vincristine—hematologic cancer	0.00672	0.0124	CbGbCtD
Ipratropium bromide—CYP2D6—Doxorubicin—hematologic cancer	0.00661	0.0122	CbGbCtD
Ipratropium bromide—CYP3A4—Etoposide—hematologic cancer	0.00616	0.0113	CbGbCtD
Ipratropium bromide—CYP3A4—Dexamethasone—hematologic cancer	0.00506	0.00932	CbGbCtD
Ipratropium bromide—CYP3A4—Doxorubicin—hematologic cancer	0.0042	0.00774	CbGbCtD
Ipratropium bromide—Headache—Mitoxantrone—hematologic cancer	5.73e-05	0.000153	CcSEcCtD
Ipratropium bromide—Nausea—Ifosfamide—hematologic cancer	5.73e-05	0.000153	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	5.71e-05	0.000153	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	5.71e-05	0.000153	CcSEcCtD
Ipratropium bromide—Myalgia—Prednisone—hematologic cancer	5.69e-05	0.000152	CcSEcCtD
Ipratropium bromide—Diarrhoea—Cisplatin—hematologic cancer	5.69e-05	0.000152	CcSEcCtD
Ipratropium bromide—Vomiting—Gemcitabine—hematologic cancer	5.67e-05	0.000151	CcSEcCtD
Ipratropium bromide—Insomnia—Dexamethasone—hematologic cancer	5.67e-05	0.000151	CcSEcCtD
Ipratropium bromide—Insomnia—Betamethasone—hematologic cancer	5.67e-05	0.000151	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	5.65e-05	0.000151	CcSEcCtD
Ipratropium bromide—Paraesthesia—Dexamethasone—hematologic cancer	5.63e-05	0.00015	CcSEcCtD
Ipratropium bromide—Paraesthesia—Betamethasone—hematologic cancer	5.63e-05	0.00015	CcSEcCtD
Ipratropium bromide—Rash—Gemcitabine—hematologic cancer	5.62e-05	0.00015	CcSEcCtD
Ipratropium bromide—Dermatitis—Gemcitabine—hematologic cancer	5.62e-05	0.00015	CcSEcCtD
Ipratropium bromide—Eye disorder—Epirubicin—hematologic cancer	5.61e-05	0.00015	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Etoposide—hematologic cancer	5.61e-05	0.00015	CcSEcCtD
Ipratropium bromide—Tinnitus—Epirubicin—hematologic cancer	5.6e-05	0.00015	CcSEcCtD
Ipratropium bromide—Haemoglobin—Doxorubicin—hematologic cancer	5.59e-05	0.000149	CcSEcCtD
Ipratropium bromide—Headache—Gemcitabine—hematologic cancer	5.59e-05	0.000149	CcSEcCtD
Ipratropium bromide—Nausea—Vincristine—hematologic cancer	5.58e-05	0.000149	CcSEcCtD
Ipratropium bromide—Flushing—Epirubicin—hematologic cancer	5.57e-05	0.000149	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Epirubicin—hematologic cancer	5.57e-05	0.000149	CcSEcCtD
Ipratropium bromide—Rhinitis—Doxorubicin—hematologic cancer	5.57e-05	0.000149	CcSEcCtD
Ipratropium bromide—Haemorrhage—Doxorubicin—hematologic cancer	5.56e-05	0.000149	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Prednisolone—hematologic cancer	5.53e-05	0.000148	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Doxorubicin—hematologic cancer	5.53e-05	0.000148	CcSEcCtD
Ipratropium bromide—Pharyngitis—Doxorubicin—hematologic cancer	5.52e-05	0.000147	CcSEcCtD
Ipratropium bromide—Dyspepsia—Dexamethasone—hematologic cancer	5.52e-05	0.000147	CcSEcCtD
Ipratropium bromide—Dyspepsia—Betamethasone—hematologic cancer	5.52e-05	0.000147	CcSEcCtD
Ipratropium bromide—Urinary tract disorder—Doxorubicin—hematologic cancer	5.49e-05	0.000147	CcSEcCtD
Ipratropium bromide—Urticaria—Triamcinolone—hematologic cancer	5.49e-05	0.000147	CcSEcCtD
Ipratropium bromide—Dysgeusia—Methotrexate—hematologic cancer	5.47e-05	0.000146	CcSEcCtD
Ipratropium bromide—Asthenia—Etoposide—hematologic cancer	5.46e-05	0.000146	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Prednisone—hematologic cancer	5.46e-05	0.000146	CcSEcCtD
Ipratropium bromide—Oedema—Prednisone—hematologic cancer	5.46e-05	0.000146	CcSEcCtD
Ipratropium bromide—Urethral disorder—Doxorubicin—hematologic cancer	5.45e-05	0.000146	CcSEcCtD
Ipratropium bromide—Nausea—Irinotecan—hematologic cancer	5.44e-05	0.000145	CcSEcCtD
Ipratropium bromide—Nausea—Mitoxantrone—hematologic cancer	5.44e-05	0.000145	CcSEcCtD
Ipratropium bromide—Immune system disorder—Epirubicin—hematologic cancer	5.43e-05	0.000145	CcSEcCtD
Ipratropium bromide—Infection—Prednisone—hematologic cancer	5.42e-05	0.000145	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Epirubicin—hematologic cancer	5.41e-05	0.000145	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.41e-05	0.000145	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.41e-05	0.000145	CcSEcCtD
Ipratropium bromide—Back pain—Methotrexate—hematologic cancer	5.4e-05	0.000144	CcSEcCtD
Ipratropium bromide—Fatigue—Betamethasone—hematologic cancer	5.4e-05	0.000144	CcSEcCtD
Ipratropium bromide—Fatigue—Dexamethasone—hematologic cancer	5.4e-05	0.000144	CcSEcCtD
Ipratropium bromide—Pruritus—Etoposide—hematologic cancer	5.39e-05	0.000144	CcSEcCtD
Ipratropium bromide—Pain—Dexamethasone—hematologic cancer	5.36e-05	0.000143	CcSEcCtD
Ipratropium bromide—Pain—Betamethasone—hematologic cancer	5.36e-05	0.000143	CcSEcCtD
Ipratropium bromide—Visual impairment—Doxorubicin—hematologic cancer	5.36e-05	0.000143	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Prednisone—hematologic cancer	5.35e-05	0.000143	CcSEcCtD
Ipratropium bromide—Tachycardia—Prednisone—hematologic cancer	5.33e-05	0.000142	CcSEcCtD
Ipratropium bromide—Skin disorder—Prednisone—hematologic cancer	5.3e-05	0.000142	CcSEcCtD
Ipratropium bromide—Nausea—Gemcitabine—hematologic cancer	5.3e-05	0.000142	CcSEcCtD
Ipratropium bromide—Vomiting—Cisplatin—hematologic cancer	5.28e-05	0.000141	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Prednisone—hematologic cancer	5.27e-05	0.000141	CcSEcCtD
Ipratropium bromide—Vision blurred—Methotrexate—hematologic cancer	5.27e-05	0.000141	CcSEcCtD
Ipratropium bromide—Rash—Cisplatin—hematologic cancer	5.24e-05	0.00014	CcSEcCtD
Ipratropium bromide—Dermatitis—Cisplatin—hematologic cancer	5.23e-05	0.00014	CcSEcCtD
Ipratropium bromide—Diarrhoea—Etoposide—hematologic cancer	5.21e-05	0.000139	CcSEcCtD
Ipratropium bromide—Eye disorder—Doxorubicin—hematologic cancer	5.19e-05	0.000139	CcSEcCtD
Ipratropium bromide—Tinnitus—Doxorubicin—hematologic cancer	5.18e-05	0.000138	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Doxorubicin—hematologic cancer	5.16e-05	0.000138	CcSEcCtD
Ipratropium bromide—Flushing—Doxorubicin—hematologic cancer	5.16e-05	0.000138	CcSEcCtD
Ipratropium bromide—Flatulence—Epirubicin—hematologic cancer	5.15e-05	0.000138	CcSEcCtD
Ipratropium bromide—Tension—Epirubicin—hematologic cancer	5.13e-05	0.000137	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.12e-05	0.000137	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Betamethasone—hematologic cancer	5.12e-05	0.000137	CcSEcCtD
Ipratropium bromide—Dysgeusia—Epirubicin—hematologic cancer	5.12e-05	0.000137	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Triamcinolone—hematologic cancer	5.09e-05	0.000136	CcSEcCtD
Ipratropium bromide—Nervousness—Epirubicin—hematologic cancer	5.08e-05	0.000136	CcSEcCtD
Ipratropium bromide—Back pain—Epirubicin—hematologic cancer	5.06e-05	0.000135	CcSEcCtD
Ipratropium bromide—Dizziness—Etoposide—hematologic cancer	5.03e-05	0.000135	CcSEcCtD
Ipratropium bromide—Immune system disorder—Doxorubicin—hematologic cancer	5.02e-05	0.000134	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Doxorubicin—hematologic cancer	5.01e-05	0.000134	CcSEcCtD
Ipratropium bromide—Urticaria—Betamethasone—hematologic cancer	4.98e-05	0.000133	CcSEcCtD
Ipratropium bromide—Urticaria—Dexamethasone—hematologic cancer	4.98e-05	0.000133	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.97e-05	0.000133	CcSEcCtD
Ipratropium bromide—Dizziness—Prednisolone—hematologic cancer	4.97e-05	0.000133	CcSEcCtD
Ipratropium bromide—Asthenia—Triamcinolone—hematologic cancer	4.95e-05	0.000132	CcSEcCtD
Ipratropium bromide—Abdominal pain—Betamethasone—hematologic cancer	4.95e-05	0.000132	CcSEcCtD
Ipratropium bromide—Abdominal pain—Dexamethasone—hematologic cancer	4.95e-05	0.000132	CcSEcCtD
Ipratropium bromide—Nausea—Cisplatin—hematologic cancer	4.94e-05	0.000132	CcSEcCtD
Ipratropium bromide—Insomnia—Prednisone—hematologic cancer	4.94e-05	0.000132	CcSEcCtD
Ipratropium bromide—Vision blurred—Epirubicin—hematologic cancer	4.93e-05	0.000132	CcSEcCtD
Ipratropium bromide—Paraesthesia—Prednisone—hematologic cancer	4.9e-05	0.000131	CcSEcCtD
Ipratropium bromide—Pruritus—Triamcinolone—hematologic cancer	4.89e-05	0.000131	CcSEcCtD
Ipratropium bromide—Cough—Methotrexate—hematologic cancer	4.88e-05	0.00013	CcSEcCtD
Ipratropium bromide—Vomiting—Etoposide—hematologic cancer	4.84e-05	0.000129	CcSEcCtD
Ipratropium bromide—Dyspepsia—Prednisone—hematologic cancer	4.8e-05	0.000128	CcSEcCtD
Ipratropium bromide—Rash—Etoposide—hematologic cancer	4.8e-05	0.000128	CcSEcCtD
Ipratropium bromide—Dermatitis—Etoposide—hematologic cancer	4.8e-05	0.000128	CcSEcCtD
Ipratropium bromide—Headache—Etoposide—hematologic cancer	4.77e-05	0.000127	CcSEcCtD
Ipratropium bromide—Flatulence—Doxorubicin—hematologic cancer	4.77e-05	0.000127	CcSEcCtD
Ipratropium bromide—Myalgia—Methotrexate—hematologic cancer	4.76e-05	0.000127	CcSEcCtD
Ipratropium bromide—Chest pain—Methotrexate—hematologic cancer	4.76e-05	0.000127	CcSEcCtD
Ipratropium bromide—Tension—Doxorubicin—hematologic cancer	4.75e-05	0.000127	CcSEcCtD
Ipratropium bromide—Dysgeusia—Doxorubicin—hematologic cancer	4.74e-05	0.000127	CcSEcCtD
Ipratropium bromide—Rash—Prednisolone—hematologic cancer	4.73e-05	0.000127	CcSEcCtD
Ipratropium bromide—Dermatitis—Prednisolone—hematologic cancer	4.73e-05	0.000126	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.72e-05	0.000126	CcSEcCtD
Ipratropium bromide—Fatigue—Prednisone—hematologic cancer	4.7e-05	0.000126	CcSEcCtD
Ipratropium bromide—Headache—Prednisolone—hematologic cancer	4.7e-05	0.000126	CcSEcCtD
Ipratropium bromide—Nervousness—Doxorubicin—hematologic cancer	4.7e-05	0.000126	CcSEcCtD
Ipratropium bromide—Back pain—Doxorubicin—hematologic cancer	4.68e-05	0.000125	CcSEcCtD
Ipratropium bromide—Constipation—Prednisone—hematologic cancer	4.67e-05	0.000125	CcSEcCtD
Ipratropium bromide—Palpitations—Epirubicin—hematologic cancer	4.62e-05	0.000123	CcSEcCtD
Ipratropium bromide—Dizziness—Triamcinolone—hematologic cancer	4.57e-05	0.000122	CcSEcCtD
Ipratropium bromide—Cough—Epirubicin—hematologic cancer	4.56e-05	0.000122	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Methotrexate—hematologic cancer	4.56e-05	0.000122	CcSEcCtD
Ipratropium bromide—Vision blurred—Doxorubicin—hematologic cancer	4.56e-05	0.000122	CcSEcCtD
Ipratropium bromide—Infection—Methotrexate—hematologic cancer	4.53e-05	0.000121	CcSEcCtD
Ipratropium bromide—Nausea—Etoposide—hematologic cancer	4.52e-05	0.000121	CcSEcCtD
Ipratropium bromide—Hypertension—Epirubicin—hematologic cancer	4.51e-05	0.000121	CcSEcCtD
Ipratropium bromide—Asthenia—Betamethasone—hematologic cancer	4.5e-05	0.00012	CcSEcCtD
Ipratropium bromide—Asthenia—Dexamethasone—hematologic cancer	4.5e-05	0.00012	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Methotrexate—hematologic cancer	4.47e-05	0.00012	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Prednisone—hematologic cancer	4.46e-05	0.000119	CcSEcCtD
Ipratropium bromide—Nausea—Prednisolone—hematologic cancer	4.46e-05	0.000119	CcSEcCtD
Ipratropium bromide—Chest pain—Epirubicin—hematologic cancer	4.45e-05	0.000119	CcSEcCtD
Ipratropium bromide—Myalgia—Epirubicin—hematologic cancer	4.45e-05	0.000119	CcSEcCtD
Ipratropium bromide—Pruritus—Betamethasone—hematologic cancer	4.43e-05	0.000118	CcSEcCtD
Ipratropium bromide—Pruritus—Dexamethasone—hematologic cancer	4.43e-05	0.000118	CcSEcCtD
Ipratropium bromide—Skin disorder—Methotrexate—hematologic cancer	4.43e-05	0.000118	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.42e-05	0.000118	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Methotrexate—hematologic cancer	4.41e-05	0.000118	CcSEcCtD
Ipratropium bromide—Vomiting—Triamcinolone—hematologic cancer	4.39e-05	0.000117	CcSEcCtD
Ipratropium bromide—Rash—Triamcinolone—hematologic cancer	4.35e-05	0.000116	CcSEcCtD
Ipratropium bromide—Dry mouth—Epirubicin—hematologic cancer	4.35e-05	0.000116	CcSEcCtD
Ipratropium bromide—Dermatitis—Triamcinolone—hematologic cancer	4.35e-05	0.000116	CcSEcCtD
Ipratropium bromide—Urticaria—Prednisone—hematologic cancer	4.33e-05	0.000116	CcSEcCtD
Ipratropium bromide—Headache—Triamcinolone—hematologic cancer	4.33e-05	0.000116	CcSEcCtD
Ipratropium bromide—Abdominal pain—Prednisone—hematologic cancer	4.31e-05	0.000115	CcSEcCtD
Ipratropium bromide—Diarrhoea—Dexamethasone—hematologic cancer	4.29e-05	0.000115	CcSEcCtD
Ipratropium bromide—Diarrhoea—Betamethasone—hematologic cancer	4.29e-05	0.000115	CcSEcCtD
Ipratropium bromide—Palpitations—Doxorubicin—hematologic cancer	4.28e-05	0.000114	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Epirubicin—hematologic cancer	4.27e-05	0.000114	CcSEcCtD
Ipratropium bromide—Oedema—Epirubicin—hematologic cancer	4.27e-05	0.000114	CcSEcCtD
Ipratropium bromide—Hypotension—Methotrexate—hematologic cancer	4.26e-05	0.000114	CcSEcCtD
Ipratropium bromide—Infection—Epirubicin—hematologic cancer	4.24e-05	0.000113	CcSEcCtD
Ipratropium bromide—Cough—Doxorubicin—hematologic cancer	4.22e-05	0.000113	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Epirubicin—hematologic cancer	4.19e-05	0.000112	CcSEcCtD
Ipratropium bromide—Hypertension—Doxorubicin—hematologic cancer	4.18e-05	0.000112	CcSEcCtD
Ipratropium bromide—Tachycardia—Epirubicin—hematologic cancer	4.17e-05	0.000111	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.15e-05	0.000111	CcSEcCtD
Ipratropium bromide—Skin disorder—Epirubicin—hematologic cancer	4.15e-05	0.000111	CcSEcCtD
Ipratropium bromide—Dizziness—Dexamethasone—hematologic cancer	4.14e-05	0.000111	CcSEcCtD
Ipratropium bromide—Dizziness—Betamethasone—hematologic cancer	4.14e-05	0.000111	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Epirubicin—hematologic cancer	4.13e-05	0.00011	CcSEcCtD
Ipratropium bromide—Insomnia—Methotrexate—hematologic cancer	4.12e-05	0.00011	CcSEcCtD
Ipratropium bromide—Myalgia—Doxorubicin—hematologic cancer	4.12e-05	0.00011	CcSEcCtD
Ipratropium bromide—Chest pain—Doxorubicin—hematologic cancer	4.12e-05	0.00011	CcSEcCtD
Ipratropium bromide—Nausea—Triamcinolone—hematologic cancer	4.1e-05	0.00011	CcSEcCtD
Ipratropium bromide—Paraesthesia—Methotrexate—hematologic cancer	4.09e-05	0.000109	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.09e-05	0.000109	CcSEcCtD
Ipratropium bromide—Dyspnoea—Methotrexate—hematologic cancer	4.07e-05	0.000109	CcSEcCtD
Ipratropium bromide—Somnolence—Methotrexate—hematologic cancer	4.05e-05	0.000108	CcSEcCtD
Ipratropium bromide—Dry mouth—Doxorubicin—hematologic cancer	4.03e-05	0.000108	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Prednisone—hematologic cancer	4.02e-05	0.000107	CcSEcCtD
Ipratropium bromide—Dyspepsia—Methotrexate—hematologic cancer	4.01e-05	0.000107	CcSEcCtD
Ipratropium bromide—Hypotension—Epirubicin—hematologic cancer	3.99e-05	0.000107	CcSEcCtD
Ipratropium bromide—Vomiting—Betamethasone—hematologic cancer	3.98e-05	0.000106	CcSEcCtD
Ipratropium bromide—Vomiting—Dexamethasone—hematologic cancer	3.98e-05	0.000106	CcSEcCtD
Ipratropium bromide—Rash—Dexamethasone—hematologic cancer	3.95e-05	0.000106	CcSEcCtD
Ipratropium bromide—Rash—Betamethasone—hematologic cancer	3.95e-05	0.000106	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Doxorubicin—hematologic cancer	3.95e-05	0.000106	CcSEcCtD
Ipratropium bromide—Oedema—Doxorubicin—hematologic cancer	3.95e-05	0.000106	CcSEcCtD
Ipratropium bromide—Dermatitis—Dexamethasone—hematologic cancer	3.95e-05	0.000105	CcSEcCtD
Ipratropium bromide—Dermatitis—Betamethasone—hematologic cancer	3.95e-05	0.000105	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.94e-05	0.000105	CcSEcCtD
Ipratropium bromide—Fatigue—Methotrexate—hematologic cancer	3.93e-05	0.000105	CcSEcCtD
Ipratropium bromide—Headache—Dexamethasone—hematologic cancer	3.93e-05	0.000105	CcSEcCtD
Ipratropium bromide—Headache—Betamethasone—hematologic cancer	3.93e-05	0.000105	CcSEcCtD
Ipratropium bromide—Infection—Doxorubicin—hematologic cancer	3.92e-05	0.000105	CcSEcCtD
Ipratropium bromide—Asthenia—Prednisone—hematologic cancer	3.91e-05	0.000105	CcSEcCtD
Ipratropium bromide—Pain—Methotrexate—hematologic cancer	3.9e-05	0.000104	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.89e-05	0.000104	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Doxorubicin—hematologic cancer	3.87e-05	0.000103	CcSEcCtD
Ipratropium bromide—Pruritus—Prednisone—hematologic cancer	3.86e-05	0.000103	CcSEcCtD
Ipratropium bromide—Insomnia—Epirubicin—hematologic cancer	3.86e-05	0.000103	CcSEcCtD
Ipratropium bromide—Tachycardia—Doxorubicin—hematologic cancer	3.85e-05	0.000103	CcSEcCtD
Ipratropium bromide—Skin disorder—Doxorubicin—hematologic cancer	3.84e-05	0.000103	CcSEcCtD
Ipratropium bromide—Paraesthesia—Epirubicin—hematologic cancer	3.83e-05	0.000102	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Doxorubicin—hematologic cancer	3.82e-05	0.000102	CcSEcCtD
Ipratropium bromide—Dyspnoea—Epirubicin—hematologic cancer	3.8e-05	0.000102	CcSEcCtD
Ipratropium bromide—Somnolence—Epirubicin—hematologic cancer	3.79e-05	0.000101	CcSEcCtD
Ipratropium bromide—Dyspepsia—Epirubicin—hematologic cancer	3.76e-05	0.0001	CcSEcCtD
Ipratropium bromide—Diarrhoea—Prednisone—hematologic cancer	3.73e-05	9.98e-05	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Methotrexate—hematologic cancer	3.73e-05	9.97e-05	CcSEcCtD
Ipratropium bromide—Nausea—Betamethasone—hematologic cancer	3.72e-05	9.95e-05	CcSEcCtD
Ipratropium bromide—Nausea—Dexamethasone—hematologic cancer	3.72e-05	9.95e-05	CcSEcCtD
Ipratropium bromide—Hypotension—Doxorubicin—hematologic cancer	3.69e-05	9.86e-05	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.68e-05	9.85e-05	CcSEcCtD
Ipratropium bromide—Fatigue—Epirubicin—hematologic cancer	3.68e-05	9.83e-05	CcSEcCtD
Ipratropium bromide—Constipation—Epirubicin—hematologic cancer	3.65e-05	9.75e-05	CcSEcCtD
Ipratropium bromide—Pain—Epirubicin—hematologic cancer	3.65e-05	9.75e-05	CcSEcCtD
Ipratropium bromide—Urticaria—Methotrexate—hematologic cancer	3.62e-05	9.68e-05	CcSEcCtD
Ipratropium bromide—Dizziness—Prednisone—hematologic cancer	3.61e-05	9.64e-05	CcSEcCtD
Ipratropium bromide—Abdominal pain—Methotrexate—hematologic cancer	3.6e-05	9.63e-05	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.6e-05	9.61e-05	CcSEcCtD
Ipratropium bromide—Insomnia—Doxorubicin—hematologic cancer	3.57e-05	9.54e-05	CcSEcCtD
Ipratropium bromide—Paraesthesia—Doxorubicin—hematologic cancer	3.55e-05	9.48e-05	CcSEcCtD
Ipratropium bromide—Dyspnoea—Doxorubicin—hematologic cancer	3.52e-05	9.41e-05	CcSEcCtD
Ipratropium bromide—Somnolence—Doxorubicin—hematologic cancer	3.51e-05	9.38e-05	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Epirubicin—hematologic cancer	3.49e-05	9.33e-05	CcSEcCtD
Ipratropium bromide—Dyspepsia—Doxorubicin—hematologic cancer	3.48e-05	9.29e-05	CcSEcCtD
Ipratropium bromide—Vomiting—Prednisone—hematologic cancer	3.47e-05	9.27e-05	CcSEcCtD
Ipratropium bromide—Rash—Prednisone—hematologic cancer	3.44e-05	9.19e-05	CcSEcCtD
Ipratropium bromide—Dermatitis—Prednisone—hematologic cancer	3.44e-05	9.19e-05	CcSEcCtD
Ipratropium bromide—Headache—Prednisone—hematologic cancer	3.42e-05	9.14e-05	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.41e-05	9.11e-05	CcSEcCtD
Ipratropium bromide—Fatigue—Doxorubicin—hematologic cancer	3.4e-05	9.1e-05	CcSEcCtD
Ipratropium bromide—Urticaria—Epirubicin—hematologic cancer	3.39e-05	9.06e-05	CcSEcCtD
Ipratropium bromide—Pain—Doxorubicin—hematologic cancer	3.38e-05	9.02e-05	CcSEcCtD
Ipratropium bromide—Constipation—Doxorubicin—hematologic cancer	3.38e-05	9.02e-05	CcSEcCtD
Ipratropium bromide—Abdominal pain—Epirubicin—hematologic cancer	3.37e-05	9.02e-05	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Methotrexate—hematologic cancer	3.36e-05	8.98e-05	CcSEcCtD
Ipratropium bromide—Asthenia—Methotrexate—hematologic cancer	3.27e-05	8.74e-05	CcSEcCtD
Ipratropium bromide—Nausea—Prednisone—hematologic cancer	3.24e-05	8.66e-05	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.23e-05	8.63e-05	CcSEcCtD
Ipratropium bromide—Pruritus—Methotrexate—hematologic cancer	3.23e-05	8.62e-05	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Epirubicin—hematologic cancer	3.14e-05	8.4e-05	CcSEcCtD
Ipratropium bromide—Urticaria—Doxorubicin—hematologic cancer	3.14e-05	8.38e-05	CcSEcCtD
Ipratropium bromide—Abdominal pain—Doxorubicin—hematologic cancer	3.12e-05	8.34e-05	CcSEcCtD
Ipratropium bromide—Diarrhoea—Methotrexate—hematologic cancer	3.12e-05	8.34e-05	CcSEcCtD
Ipratropium bromide—Asthenia—Epirubicin—hematologic cancer	3.06e-05	8.18e-05	CcSEcCtD
Ipratropium bromide—Pruritus—Epirubicin—hematologic cancer	3.02e-05	8.07e-05	CcSEcCtD
Ipratropium bromide—Dizziness—Methotrexate—hematologic cancer	3.02e-05	8.06e-05	CcSEcCtD
Ipratropium bromide—Diarrhoea—Epirubicin—hematologic cancer	2.92e-05	7.8e-05	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Doxorubicin—hematologic cancer	2.91e-05	7.77e-05	CcSEcCtD
Ipratropium bromide—Vomiting—Methotrexate—hematologic cancer	2.9e-05	7.75e-05	CcSEcCtD
Ipratropium bromide—Rash—Methotrexate—hematologic cancer	2.88e-05	7.68e-05	CcSEcCtD
Ipratropium bromide—Dermatitis—Methotrexate—hematologic cancer	2.87e-05	7.68e-05	CcSEcCtD
Ipratropium bromide—Headache—Methotrexate—hematologic cancer	2.86e-05	7.63e-05	CcSEcCtD
Ipratropium bromide—Asthenia—Doxorubicin—hematologic cancer	2.83e-05	7.57e-05	CcSEcCtD
Ipratropium bromide—Dizziness—Epirubicin—hematologic cancer	2.82e-05	7.54e-05	CcSEcCtD
Ipratropium bromide—Pruritus—Doxorubicin—hematologic cancer	2.79e-05	7.47e-05	CcSEcCtD
Ipratropium bromide—Vomiting—Epirubicin—hematologic cancer	2.71e-05	7.25e-05	CcSEcCtD
Ipratropium bromide—Nausea—Methotrexate—hematologic cancer	2.71e-05	7.24e-05	CcSEcCtD
Ipratropium bromide—Diarrhoea—Doxorubicin—hematologic cancer	2.7e-05	7.22e-05	CcSEcCtD
Ipratropium bromide—Rash—Epirubicin—hematologic cancer	2.69e-05	7.19e-05	CcSEcCtD
Ipratropium bromide—Dermatitis—Epirubicin—hematologic cancer	2.69e-05	7.18e-05	CcSEcCtD
Ipratropium bromide—Headache—Epirubicin—hematologic cancer	2.67e-05	7.14e-05	CcSEcCtD
Ipratropium bromide—Dizziness—Doxorubicin—hematologic cancer	2.61e-05	6.98e-05	CcSEcCtD
Ipratropium bromide—Nausea—Epirubicin—hematologic cancer	2.53e-05	6.77e-05	CcSEcCtD
Ipratropium bromide—Vomiting—Doxorubicin—hematologic cancer	2.51e-05	6.71e-05	CcSEcCtD
Ipratropium bromide—Rash—Doxorubicin—hematologic cancer	2.49e-05	6.65e-05	CcSEcCtD
Ipratropium bromide—Dermatitis—Doxorubicin—hematologic cancer	2.49e-05	6.65e-05	CcSEcCtD
Ipratropium bromide—Headache—Doxorubicin—hematologic cancer	2.47e-05	6.61e-05	CcSEcCtD
Ipratropium bromide—Nausea—Doxorubicin—hematologic cancer	2.35e-05	6.27e-05	CcSEcCtD
Ipratropium bromide—CHRM1—Signaling Pathways—TSC2—hematologic cancer	7.03e-06	8.5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—TSC2—hematologic cancer	7.01e-06	8.47e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—PIK3CA—hematologic cancer	6.98e-06	8.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MDM2—hematologic cancer	6.95e-06	8.4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—TSC2—hematologic cancer	6.94e-06	8.39e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—CREBBP—hematologic cancer	6.86e-06	8.3e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NUP98—hematologic cancer	6.81e-06	8.23e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	6.76e-06	8.18e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MTOR—hematologic cancer	6.76e-06	8.17e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—PIK3CB—hematologic cancer	6.76e-06	8.17e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	6.74e-06	8.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	6.7e-06	8.09e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	6.68e-06	8.07e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	6.68e-06	8.07e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ADCY7—hematologic cancer	6.61e-06	7.99e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NCOA3—hematologic cancer	6.61e-06	7.99e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	6.61e-06	7.99e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—ESR1—hematologic cancer	6.57e-06	7.94e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NUP214—hematologic cancer	6.57e-06	7.94e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—ESR1—hematologic cancer	6.55e-06	7.92e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3CD—hematologic cancer	6.51e-06	7.87e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—FN1—hematologic cancer	6.49e-06	7.84e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—GSTP1—hematologic cancer	6.49e-06	7.84e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—ESR1—hematologic cancer	6.49e-06	7.84e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—FN1—hematologic cancer	6.47e-06	7.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	6.45e-06	7.8e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.43e-06	7.78e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—MTR—hematologic cancer	6.43e-06	7.78e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—ALB—hematologic cancer	6.43e-06	7.77e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	6.41e-06	7.75e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—BAD—hematologic cancer	6.41e-06	7.75e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—FN1—hematologic cancer	6.41e-06	7.74e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—BAD—hematologic cancer	6.39e-06	7.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	6.39e-06	7.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	6.35e-06	7.68e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	6.34e-06	7.67e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	6.33e-06	7.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—BAD—hematologic cancer	6.33e-06	7.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	6.33e-06	7.65e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ENO2—hematologic cancer	6.31e-06	7.63e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	6.27e-06	7.58e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	6.27e-06	7.58e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CD80—hematologic cancer	6.22e-06	7.52e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CASP3—hematologic cancer	6.22e-06	7.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—KIT—hematologic cancer	6.21e-06	7.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	6.21e-06	7.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	6.21e-06	7.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—IL2—hematologic cancer	6.21e-06	7.5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CD80—hematologic cancer	6.2e-06	7.5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	6.19e-06	7.48e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—KIT—hematologic cancer	6.19e-06	7.48e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	6.19e-06	7.48e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—IL6—hematologic cancer	6.18e-06	7.46e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3R1—hematologic cancer	6.15e-06	7.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CD80—hematologic cancer	6.14e-06	7.42e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ABCB1—hematologic cancer	6.14e-06	7.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	6.13e-06	7.41e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—KIT—hematologic cancer	6.13e-06	7.41e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	6.13e-06	7.41e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.12e-06	7.4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	6.1e-06	7.37e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	6.08e-06	7.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CCND1—hematologic cancer	6.05e-06	7.31e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—JUN—hematologic cancer	6.04e-06	7.3e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	6.02e-06	7.28e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—SDC1—hematologic cancer	5.98e-06	7.23e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—GSTM1—hematologic cancer	5.96e-06	7.21e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—NCOR1—hematologic cancer	5.96e-06	7.21e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	5.95e-06	7.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	5.93e-06	7.17e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CREB1—hematologic cancer	5.91e-06	7.14e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CREB1—hematologic cancer	5.89e-06	7.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	5.87e-06	7.1e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	5.85e-06	7.07e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—PTEN—hematologic cancer	5.84e-06	7.06e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—BRAF—hematologic cancer	5.84e-06	7.06e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CREB1—hematologic cancer	5.84e-06	7.05e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—BRAF—hematologic cancer	5.82e-06	7.03e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CCL2—hematologic cancer	5.78e-06	6.99e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IL6R—hematologic cancer	5.77e-06	6.97e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CCL2—hematologic cancer	5.77e-06	6.97e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—BRAF—hematologic cancer	5.76e-06	6.96e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	5.76e-06	6.96e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IL6R—hematologic cancer	5.75e-06	6.95e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	5.74e-06	6.94e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	5.71e-06	6.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CCL2—hematologic cancer	5.71e-06	6.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	5.7e-06	6.89e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IL6R—hematologic cancer	5.69e-06	6.88e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	5.68e-06	6.87e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3CB—hematologic cancer	5.67e-06	6.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—EP300—hematologic cancer	5.57e-06	6.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	5.5e-06	6.64e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	5.48e-06	6.62e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	5.46e-06	6.6e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	5.44e-06	6.58e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	5.43e-06	6.56e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—SRC—hematologic cancer	5.42e-06	6.55e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.41e-06	6.54e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	5.39e-06	6.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	5.39e-06	6.51e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	5.35e-06	6.46e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	5.34e-06	6.45e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	5.33e-06	6.44e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	5.28e-06	6.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	5.28e-06	6.38e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—MTHFR—hematologic cancer	5.27e-06	6.37e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—FGF2—hematologic cancer	5.23e-06	6.32e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—STAT3—hematologic cancer	5.22e-06	6.31e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—FGF2—hematologic cancer	5.21e-06	6.3e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—NRAS—hematologic cancer	5.21e-06	6.3e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—FGF2—hematologic cancer	5.16e-06	6.24e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	5.16e-06	6.23e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	5.14e-06	6.21e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	5.09e-06	6.15e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NQO1—hematologic cancer	5.09e-06	6.15e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CD44—hematologic cancer	5.09e-06	6.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—JAK2—hematologic cancer	5.01e-06	6.06e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—JAK2—hematologic cancer	5e-06	6.04e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	4.99e-06	6.03e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—JAK2—hematologic cancer	4.95e-06	5.98e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	4.91e-06	5.94e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PTEN—hematologic cancer	4.9e-06	5.92e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	4.9e-06	5.92e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MDM2—hematologic cancer	4.89e-06	5.91e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MDM2—hematologic cancer	4.88e-06	5.89e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—MYC—hematologic cancer	4.85e-06	5.87e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	4.85e-06	5.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	4.84e-06	5.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MDM2—hematologic cancer	4.83e-06	5.84e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CYCS—hematologic cancer	4.81e-06	5.82e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.78e-06	5.78e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MTOR—hematologic cancer	4.76e-06	5.75e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	4.76e-06	5.75e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MTOR—hematologic cancer	4.74e-06	5.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	4.74e-06	5.73e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MTOR—hematologic cancer	4.7e-06	5.68e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	4.7e-06	5.68e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—EP300—hematologic cancer	4.68e-06	5.65e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	4.54e-06	5.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	4.53e-06	5.47e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	4.49e-06	5.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—KRAS—hematologic cancer	4.48e-06	5.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	4.47e-06	5.4e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	4.45e-06	5.38e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	4.43e-06	5.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	4.42e-06	5.34e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	4.41e-06	5.33e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	4.4e-06	5.32e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CASP3—hematologic cancer	4.38e-06	5.29e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IL2—hematologic cancer	4.37e-06	5.28e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CASP3—hematologic cancer	4.36e-06	5.27e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	4.36e-06	5.27e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IL2—hematologic cancer	4.36e-06	5.27e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—IL6—hematologic cancer	4.35e-06	5.26e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—IL6—hematologic cancer	4.34e-06	5.24e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CASP3—hematologic cancer	4.32e-06	5.22e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IL2—hematologic cancer	4.31e-06	5.21e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—IL6—hematologic cancer	4.29e-06	5.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CCND1—hematologic cancer	4.26e-06	5.15e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—JUN—hematologic cancer	4.25e-06	5.14e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CCND1—hematologic cancer	4.25e-06	5.13e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.24e-06	5.13e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—JUN—hematologic cancer	4.24e-06	5.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CCND1—hematologic cancer	4.21e-06	5.08e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—JUN—hematologic cancer	4.2e-06	5.07e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	4.12e-06	4.98e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	4.12e-06	4.98e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PTEN—hematologic cancer	4.11e-06	4.97e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	4.11e-06	4.97e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—CREBBP—hematologic cancer	4.1e-06	4.96e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PTEN—hematologic cancer	4.1e-06	4.95e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	4.07e-06	4.92e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PTEN—hematologic cancer	4.06e-06	4.91e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	4.02e-06	4.86e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.02e-06	4.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	4.01e-06	4.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	4.01e-06	4.85e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	4e-06	4.83e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—TP53—hematologic cancer	3.99e-06	4.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	3.97e-06	4.8e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	3.96e-06	4.79e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—EP300—hematologic cancer	3.92e-06	4.74e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—EP300—hematologic cancer	3.91e-06	4.72e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.9e-06	4.71e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.9e-06	4.71e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.89e-06	4.7e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—EP300—hematologic cancer	3.87e-06	4.68e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—ALB—hematologic cancer	3.84e-06	4.64e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—SRC—hematologic cancer	3.81e-06	4.61e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—HRAS—hematologic cancer	3.81e-06	4.61e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—SRC—hematologic cancer	3.8e-06	4.59e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—SRC—hematologic cancer	3.76e-06	4.55e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	3.71e-06	4.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	3.7e-06	4.47e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—STAT3—hematologic cancer	3.68e-06	4.44e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.68e-06	4.44e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—NRAS—hematologic cancer	3.67e-06	4.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	3.67e-06	4.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—STAT3—hematologic cancer	3.67e-06	4.43e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—NRAS—hematologic cancer	3.66e-06	4.42e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—IL6—hematologic cancer	3.65e-06	4.41e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—STAT3—hematologic cancer	3.63e-06	4.39e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—NRAS—hematologic cancer	3.62e-06	4.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	3.51e-06	4.25e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	3.5e-06	4.23e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	3.47e-06	4.19e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—PIK3CA—hematologic cancer	3.46e-06	4.18e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.45e-06	4.16e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—MYC—hematologic cancer	3.42e-06	4.13e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	3.41e-06	4.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—MYC—hematologic cancer	3.41e-06	4.12e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	3.4e-06	4.11e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	3.39e-06	4.1e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—MYC—hematologic cancer	3.37e-06	4.08e-05	CbGpPWpGaD
Ipratropium bromide—CHRM5—Signaling Pathways—AKT1—hematologic cancer	3.37e-06	4.07e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	3.37e-06	4.07e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—KRAS—hematologic cancer	3.16e-06	3.82e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—KRAS—hematologic cancer	3.15e-06	3.8e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—KRAS—hematologic cancer	3.12e-06	3.77e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PTEN—hematologic cancer	2.93e-06	3.54e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.9e-06	3.51e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.89e-06	3.5e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	2.89e-06	3.49e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	2.86e-06	3.46e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Metabolism—AKT1—hematologic cancer	2.83e-06	3.41e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.81e-06	3.39e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.8e-06	3.38e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—EP300—hematologic cancer	2.8e-06	3.38e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—TP53—hematologic cancer	2.77e-06	3.35e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.68e-06	3.24e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.68e-06	3.24e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.68e-06	3.23e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.65e-06	3.2e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—IL6—hematologic cancer	2.57e-06	3.1e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—IL6—hematologic cancer	2.56e-06	3.09e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.54e-06	3.08e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—IL6—hematologic cancer	2.54e-06	3.06e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—ALB—hematologic cancer	2.51e-06	3.04e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.4e-06	2.9e-05	CbGpPWpGaD
Ipratropium bromide—CHRM1—Signaling Pathways—AKT1—hematologic cancer	2.37e-06	2.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM3—Signaling Pathways—AKT1—hematologic cancer	2.36e-06	2.86e-05	CbGpPWpGaD
Ipratropium bromide—CHRM2—Signaling Pathways—AKT1—hematologic cancer	2.34e-06	2.83e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.22e-06	2.68e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.07e-06	2.5e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PTEN—hematologic cancer	1.92e-06	2.32e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—EP300—hematologic cancer	1.83e-06	2.21e-05	CbGpPWpGaD
Ipratropium bromide—CYP2D6—Metabolism—AKT1—hematologic cancer	1.69e-06	2.04e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.35e-06	1.63e-05	CbGpPWpGaD
Ipratropium bromide—CYP3A4—Metabolism—AKT1—hematologic cancer	1.1e-06	1.33e-05	CbGpPWpGaD
